A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 21 Jan 2017 Results (n=828) from NCT00105443 and NCT00492752 trials assessing the correlation between time to progression (TTP) and overall survival, presented at the 2017 Gastrointestinal Cancers Symposium.
    • 11 Oct 2016 Results from SHARP and Asia Pacific trials assessing the association of overall survival with tumor growth rate (TGR) presented at the 41st European Society for Medical Oncology Congress.
    • 10 Jan 2012 Results of subgroup analyses published in the European Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top